Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer

Lung Cancer

Volumn 20, Issue 2, 1998, Pages 117-125

  Gotoh, Kunihiko ^a,b   Yatabe, Yasushi ^a   Sugiura, Takahiko ^a   Takagi, Kenzo ^b   Ogawa, Makoto ^a   Takahashi, Takashi ^a   Takahashi, Toshitada ^a   Mitsudomi, Tetsuya ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer vaccine; Immunotherapy; Lung cancer; MAGE 3

Indexed keywords

HLA A1 ANTIGEN; HLA A2 ANTIGEN; TUMOR ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE EXPRESSION; HLA SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; DNA PRIMERS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENOTYPE; HLA ANTIGENS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIGENE FAMILY; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 0032077720     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(98)00017-8     Document Type: Article

References (31)

1. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1991;1643-1647.
2. Gaugler B., Van den Eynde B., van der Bruggen P., Romero P., Gaforio J.J., De Plaen E., Lethe B., Brasseur F., Boon T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 179:1994;921-930.
3. De Plaen E., Arden K., Traversari C., Gaforio J.J., Szikora J.P., De Smet C., Brasseur F., van der Bruggen P., Lethe B., Lurquin C., Brasseur R., Chomez P., De Backer O., Cavenee W., Boon T. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics. 40:1994;360-369.
4. Traversari C., van der Bruggen P., Luescher I.F., Lurquin C., Chomez P., Van Pel A., De Plaen E., Amar-Costesec A., Boon T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med. 176:1992;1453-1457.
5. Weynants P., Lethe B., Brasseur F., Marchand M., Boon T. Expression of mage genes by non-small-cell lung carcinomas. Int J Cancer. 56:1994;826-829.
6. van der Bruggen P., Szikora J.P., Boel P., Wildmann C., Somville M., Sensi M., Boon T. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur J Immunol. 24:1994;2134-2140.
7. van der Bruggen P., Bastin J., Gajewski T., Coulie P.G., Boel P., De Smet C., Traversari C., Townsend A., Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol. 24:1994;3038-3043.
8. Shichijo S., Hayashi A., Takamori S., Tsunosue R., Hoshino T., Sakata M., Kuramoto T., Oizumi K., Itoh K. Detection of MAGE-4 protein in lung cancers. Int J Cancer. 64:1995;158-165.
9. Sambrook J, Fritsch EF, Maniatis T. Isolation of total RNA by extraction with strong denaturants. In: Sambrook J, editor. Molecular Cloning: A Laboratory Manual, vol. 1. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989:7.18-7.25.
10. Brasseur F., Marchand M., Vanwijck R., Herin M., Lethe B., Chomez P., Boon T. Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors [letter]. Int J Cancer. 52:1992;839-841.
11. Inoue H., Li J., Honda M., Nakashima H., Shibuta K., Arinaga S., Ueo H., Mori M., Akiyoshi T. MAGE-1 mRNA expression in gastric carcinoma [letter]. Int J Cancer. 64:1995;76-77.
12. Tanaka F., Fujie T., Go H., Baba K., Mori M., Takesako K., Akiyoshi T. Efficient induction of antitumor cytotoxic T lymphocytes from a healthy donor using HLA-A2-restricted MAGE-3 peptide in vitro. Cancer Immunol Immunother. 44:1997;21-26.
13. Tokunaga K., Nakamura Y., Sakata K., Fujimori K., Ohkubo M., Sawada K., Sakiyama S. Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. Cancer Res. 47:1987;5616-5619.
14. Browning M.J., Krausa P., Rowan A., Bicknell D.C., Bodmer J.G., Bodmer W.F. Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines. Proc Natl Acad Sci USA. 90:1993;2842-2845.
15. Barnstable C.J., Bodmer W.F., Brown G., Galfre G., Milstein C., Williams A.F., Ziegler A. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell. 14:1978;9-20.
16. Hsu S.M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 29:1981;577-580.
17. Doyle A., Martin W.J., Funa K., Gazdar A., Carney D., Martin S.E., Linnoila I., Cuttitta F., Mulshine J., Bunn P., Minna J. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med. 161:1985;1135-1151.
18. Passlick B., Izbicki J.R., Simmel S., Kubuschok B., Karg O., Habekost M., Thetter O., Schweiberer L., Pantel K. Expression of major histocompatibility class I and class II antigens and intercellular adhesion molecule-1 on operable non-small cell lung carcinomas: frequency and prognostic significance. Eur J Cancer. 30A:1994;376-381.
19. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
20. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50(1):1966;163-170.
21. Singal D.P., Ye M., Qiu X. Molecular basis for lack of expression of HLA class I antigens in human small-cell lung carcinoma cell lines. Int J Cancer. 68:1996;629-636.
22. Dong R.P., Kimura A., Okubo R., Shinagawa H., Tamai H., Nishimura Y., Sasazuki T. HLA-A and DPB1 loci confer susceptibility to Graves' disease. Hum Immunol. 35:1992;165-172.
23. Redondo M., Ruiz-Cabello F., Concha A., Cabrera T., Perez-Ayala M., Oliva M.R., Garrido F. Altered HLA class I expression in non-small cell lung cancer is independent of c-myc activation. Cancer Res. 51:1991;2463-2468.
24. Redondo M., Concha A., Oldiviela R., Cueto A., Gonzalez A., Garrido F., Ruiz-Cabello F. Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters. Cancer Res. 51:1991;4948-4954.
25. Korkolopoulou P., Kaklamanis L., Pezzella F., Harris A.L., Gatter K.C. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer. 73:1996;148-153.
26. Ferrone S., Marincola F.M. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. [Review]. Immunol Today. 16:1995;487-494.
27. 2 microglobulin abnormalities in human lung and breast cancer. Int J Cancer. 67:1996;756-763.
28. Restifo N.P., Esquivel F., Kawakami Y., Yewdell J.W., Mule J.J., Rosenberg S.A., Bennink J.R. Identification of human cancers deficient in antigen processing. J Exp Med. 177:1993;265-272.
29. Wiedenfeld E.A., Fernandez-Vina M., Berzofsky J.A., Carbone D.P. Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif. Cancer Res. 54:1994;1175-1177.
30. Nistico P., Mottolese M., Mammi C., Benevolo M., Del Bello D., Rubiu O., Gentile F.P., Botti C., Venturo I., Natali P.G. Low frequency of ErbB-2 proto-oncogene overexpression in human leukocyte antigen-A2-positive breast cancer patients. J Natl Cancer Inst. 89:1997;319-321.
31. Tanaka F., Fujie T., Tahara K., Mori M., Takesako K., Sette A., Celis E., Akiyoshi T. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res. 57:1997;4465-4468.